Benzodiazepine receptor ligands: a patent review (2006 – 2012)

Bibliography

• Olsen RW, Sieghart W. GABAA Receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology 2009;56:141-8
   PubMed Web of Science ®Google Scholar
• Mohler H. GABAA receptor diversity and pharmacology. Cell Tissue Res 2006;326:505-16
   PubMed Web of Science ®Google Scholar
• Olsen RW, Sieghart W. International union of pharmacology. LXX. subtypes of gamma-aminobutyric acid a receptors: classification on the basis of subunit composition, pharmacology and function.Update10.1124/pr.108.00505. Pharmacol Rev 2008;60:243-60
   PubMed Web of Science ®Google Scholar
• Uusi-Oukari M, Korpi ER. Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev 2010;62:97-135
   PubMed Web of Science ®Google Scholar
• Atack JR. The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 2005;14:601-18
   PubMed Web of Science ®Google Scholar
• McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepine are mediated by the GABAA receptor a1 subtype. Nat Neurosci 2000;3:587-92
   PubMed Web of Science ®Google Scholar
• Atack JR. GABAA Receptor subtype-selective modulators. I. 2/3-Selective agonists as non-sedating anxiolytics. Curr Top Med Chem 2011;11:1176-202
   PubMed Web of Science ®Google Scholar
• Atack JR. GABAA Receptor subtype-selective modulators. II. 5-selective inverse agonists for cognition enhancement. Curr Top Med Chem 2011;11:1203-14
   PubMed Web of Science ®Google Scholar
• Vinkers CH, Mirza NR, Olivier B, Kahn RS. The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline. doi:10.1517/13543784.2010.513382. Expert Opin Investig Drugs 2010;19:1217-33
   PubMed Web of Science ®Google Scholar
• Charych EI, Liu F, Moss SJ, Brandon NJ. GABAA receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders. Neuropharmacology 2009; In Press; Corrected Proof
   PubMed Web of Science ®Google Scholar
• Vollenweider I, Smith KS, Keist R, Rudolph U. Antidepressant-like properties of I±2-containing GABAA receptors. Behav Brain Res 2011;217:77-80
   PubMed Web of Science ®Google Scholar
• Engin E, Liu J, Rudolph U. Alpha2-containing GABAA receptors: A target for the development of novel treatment strategies for CNS disorders. Pharmacol Ther 2012;136:142-52
   PubMed Web of Science ®Google Scholar
• Smith KS, Rudolph U. Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABAA receptor subtypes. Neuropharmacology 2012;62:54-62
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU, Mohler H, Di Lio A. GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol Sci 2009;30:397-402
   PubMed Web of Science ®Google Scholar
• Di Lio A, Benke D, Besson M, et al. HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology 2011;60:626-32
   PubMed Web of Science ®Google Scholar
• Knabl J, Zeilhofer UB, Crestani F, et al. Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain 2009;141:233-8
   PubMed Web of Science ®Google Scholar
• Rudolph U, Knoflach FDR. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. 2011;10:685-97
   Google Scholar
• Mirza NR, Munro G. The role of GABAA receptor subtypes as analgesic targets. Drug News Perspect 2010;23:351-60
   PubMed Web of Science ®Google Scholar
• Munro G, Ahring PK, Mirza NR. Developing analgesics by enhancing spinal inhibition after injury: GABAA receptor subtypes as novel targets. Trends Pharmacol Sci 2009;30:453-9
   PubMed Web of Science ®Google Scholar
• Munro G, Lopez-Garcia JA, Rivera-Arconada I, et al. Comparison of the Novel Subtype-Selective GABAA Receptor-Positive Allosteric Modulator NS11394 [3'-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with Diazepam, Zolpidem, Bretazenil, and Gaboxadol in Rat Models of Inflammatory and Neuropathic Pain. J Pharmacol Exp Ther 2008;327:969-81
   PubMed Web of Science ®Google Scholar
• Zeilhofer HU, Benke D, Yevenes GE. Chronic pain states: pharmacological strategies to restore diminished inhibitory spinal pain control. Annu Rev Pharmacol Toxicol 2012;52:111-33
   PubMed Web of Science ®Google Scholar
• Koh MT, Rosenzweig-Lipson S, Gallagher M. Selective GABAA alpha5 positive allosteric modulators improve cognitive function in aged rats with memory impairment. Neuropharmacology 2013;64:145-52
   PubMed Web of Science ®Google Scholar
• Braudeau J, Delatour B, Duchon A, et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol 2011;25:1030-42
   PubMed Web of Science ®Google Scholar
• Mohler H. Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model. Biochem Pharmacol 2012;84:994-9
   PubMed Web of Science ®Google Scholar
• Ng HJ, Whittemore ER, Tran MB, et al. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Nat Acad Sci USA 2007;104:8059-64
   PubMed Web of Science ®Google Scholar
• Liu XF, Chang H-F, Schmiesing RJ, et al. Developing dual functional allosteric modulators of GABAA receptors. Bioorg Med Chem 2010;18:8374-82
   PubMed Web of Science ®Google Scholar
• la Fougere C, Rominger A, Forster S, et al. PET and SPECT in epilepsy: a critical review. Epilepsy Behav 2009;15:50-5
   PubMed Web of Science ®Google Scholar
• Hoepping A, Diekers M, Deuter-Conrad W, et al. Synthesis of fluorine substituted pyrazolopyrimidines as potential leads for the development of PET-imaging agents for the GABAA receptors. Bioorg Med Chem 2008;16:1184-94
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche, Inc. Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives. US2006079507; 2006
   Google Scholar
• Hoffmann-La Roche, Inc. Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives. US2006084642; 2006
   Google Scholar
• Hoffmann-La Roche, Inc. Substituted imidazo[1,5-a] [1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives. US2006128691; 2006
   Google Scholar
• Hoffmann-La Roche, Inc. Halogen substituted benzodiazepine derivatives. WO2006045429; 2006
   Google Scholar
• Hoffmann-La Roche, Inc. Imidazobenzodiazepine derivatives. WO2007042421; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Aryl-isoxazol-4-yl-imidazole derivatives. WO2007074078; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treament of Alzheimer's deseases via GABA receptors. WO2007082806; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives. WO2007074089; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Aryl-isoxazolo-4-yl-oxadiazole derivatives. WO2007071598; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. 3-Aryl-isoxazole-4-carbonyl-indole derivatives. US2007105922; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo derivatives. US2007066668; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Aryl-4-ethynyl-isoxazole derivatives. WO2007137954; 2007
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazole-imidazole derivatives. WO2009000662; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyridine derivatives. WO2009071476; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo -pyridine derivatives. US2009143385; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyrazine derivatives. US2009143407; 2009
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyridazine derivatives. WO2010127968; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Hydroxymethyl isoxazole derivatives as GABAA modulators. WO2010112475; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazole-thiazole derivatives as GABAA receptor inverse agonist for use in the treatment of cognitive disorders. WO2010127974; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyrazole derivatives. WO2010127975; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyridine derivatives. WO2010127976; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyridine derivatives as GABA modulators. WO2010127978; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazolo-pyrazine derivatives. US2010256154; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazoles/O-pyridine derivatives with ethyl and ethenyl linker. US2010216845; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Isoxazole-isoxazoles and isoxazole-isiothiazoles. US2010210651; 2010
   Google Scholar
• Hoffmann-La Roche, Inc. Novel triazole compounds III. WO2012076590; 2012
   Google Scholar
• Hoffmann-La Roche, Inc. Novel triazole compounds I. WO2012062687; 2012
   Google Scholar
• The Governing Council of the University of Toronto. Methods for the prevention and/or treatment of memory. WO2012051707; 2012
   Google Scholar
• Atack JR, Bayley PJ, Seabrook GR, et al. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for [alpha]5-containing GABAA receptors. Neuropharmacology 2006;51:1023-9
   PubMed Web of Science ®Google Scholar
• Atack JR, Maubach K, Wafford KA, et al. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d][1,2,4]triazine (MRK-016),a GABAA Receptor alpha5 subtype selective inverse agonist. J Pharmacol Exp Ther 2009;331:470-84
   PubMed Web of Science ®Google Scholar
• Cambridge Enterprise Ltd. Use of GABAA receptor antagonists to treat cognitive impairment in patients with psychiatric conditions. WO2009016329; 2009
   Google Scholar
• Savic MM, Obradovic DI, Ugresic ND, et al. Bidirectional effects of benzodiazepine binding site ligands in the passive avoidance tasck: differential antagonism by flumazenil and beta-CCt. Behav Brain Res 2005;158:293-300
   PubMed Web of Science ®Google Scholar
• Centre National de la Recherche Scientifique-CNRS. Composition and method for treating cognitive impairments in Down syndrom subject. WO2011024115; 2011
   Google Scholar
• Knust H, Achermann G, Ballard T, et al. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA [alpha]5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett 2009;19:5940-4
   PubMed Web of Science ®Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Cognitive function. US20121574445; 2012
   Google Scholar
• Wisys Technology Foundation, Inc. Gabaergic agents to treat memory deficits. US7595395; 2009
   Google Scholar
• Savic MM, Clayton T, Furtmuller R, et al. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing [alpha]5 subunits, improves passive, but not active, avoidance learning in rats. Brain Res 2008;1208:150-9
   PubMed Web of Science ®Google Scholar
• Han D, Holger Forsterling F, Li X, et al. A study of the structure-activity relationship of GABA A-benzodiazepine receptor bivalent ligands by conformational analysis with low temperature NMR and X-ray analysis. Bioorg Med Chem 2008;16:8853-62
   PubMed Web of Science ®Google Scholar
• Cook James. Gabaergic agents to treat memory deficits. US2010130479; 2010
   Google Scholar
• The Regents of the University of California. Substituted heterocycles and their use as allosteric modulators af nicotinic and GABAA receptors. WO2010104843; 2010
   Google Scholar
• The Johns Hopkins University. Methods for characterizing and treating cognitive impairment in aging and disease. WO2007019312; 2007
   Google Scholar
• Agenebio, Inc. Benzodiazepine derivatives, compositions and methods for treating cognitive impairment. WO2012068149; 2012
   Google Scholar
• Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment. WO2012068161; 2012
   Google Scholar
• Astrazeneca AB. Substituted cinnoline derivatives as GABAA receptor modulators and method for their synthesis. WO2007073283; 2007
   Google Scholar
• Astrazeneca AB. Uses of cinnoline compounds to treat schizophrenia. WO2008155573; 2008
   Google Scholar
• Astrazeneca AB. Cinnoline compounds, their preparation, and their use. WO2011021979; 2011
   Google Scholar
• Astrazeneca AB. Compound and uses thereof - 848. WO2008155572; 2008
   Google Scholar
• Universitat Zurich. Selective therapeutic agents for pain suppression. WO2006061428; 2006
   Google Scholar
• Cook James. Selective agents for pain suppression. US2010317619; 2010
   Google Scholar
• Wisys Technologys Foundation. Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hgypnotic and ataxic effects. US7618958; 2009
   Google Scholar
• Ferrer Internacional SA. N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, end composition, and methods related thereto. EP1648897; 2008
   Google Scholar
• Ferrer Internacional SA. 7-Substituted 3-nitropyrazolo[1,5-a]pyrimidines. EP1648896; 2008
   Google Scholar
• Ferrer Internacional SA. Halogenated pyrazolo[1,5-a]pyrimidines processess, uses as GABAA receptors ligands, compositions and intermediates. EP1899343; 2010
   Google Scholar
• Ferrer Internacional SA. Pyrazolo[1,5-a]pyrimidines processess, uses and compositions. WO2008015253; 2008
   Google Scholar
• Ferrer Internacional SA. 1H-Quinolin-4-one compounds,with affinity for the GABA receptor, processes, uses and compositions. US2010168099; 2010
   Google Scholar
• Ferrer Internacional SA. Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto. WO2006051063; 2006
   Google Scholar
• Ferrer Internacional SA. Imidazo[1,2-a]pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof. WO2007077159; 2007
   Google Scholar
• Ferrer Internacional SA. N-[3-Imidazo[1,5-a]pyrimidin-4-yl)phenyl]-sulfonamides and N-[3-Imidazo[1,5-a]pyrimidin-4-yl)phenyl]-carboxamides and their use as GABAA receptor modulators. WO2006084835; 2006
   Google Scholar
• Ferrer Internacional SA. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands. WO2007110437; 2007
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006111517; 2006
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006111516; 2006
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006108800; 2006
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2006148856; 2006
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2007065864; 2007
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2007110374; 2007
   Google Scholar
• Neurosearch AS. 1,5,7-Trisubstituted benzimidazole derivatives and their use for modulating the GABAA receptor complex. US2007021482; 2007
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055124; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055125; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055126; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055127; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055128; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055129; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055130; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055131; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055132; 2010
   Google Scholar
• Neurosearch AS. Benzimidazole derivatives and their use for modulating the GABAA receptor complex. WO2010055133; 2010
   Google Scholar
• Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042543; 2007
   Google Scholar
• Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042544; 2007
   Google Scholar
• Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042545; 2007
   Google Scholar
• Neurosearch AS. Imidazole derivatives and their use for modulating the GABAA receptor complex. WO2007042546; 2007
   Google Scholar
• Neurogen Corp. Thiazolylmethyl and oxazolylmethyl heteroaryl derivatives. WO2006093911; 2006
   Google Scholar
• Neurogen Corp. Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives. WO2006078891; 2006
   Google Scholar
• Neurogen Corp. Pyrazolylmethyl heteroaryl derivatives. WO2006052546; 2006
   Google Scholar
• Neurogen Corp. Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands. US2006014746; 2006
   Google Scholar
• Neurogen Corp. Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands. EP1880998; 2008
   Google Scholar
• Neurogen Corp. Imidazo-pyrimidines, triazolo-pyrimidines: and related benzodiazepine receptor ligands. US7271170; 2007
   Google Scholar
• Neurogen Corp. Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands. US20090023737; 2009
   Google Scholar
• Neurogen Corp. Arylacid pyrimidinyl amides, pyridazinyl methyl amides and related compounds. US20061353367; 2006
   Google Scholar
• Neurogen Corp. Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAA receptors. US2006160842; 2006
   Google Scholar
• Neurogen Corp. Bicyclic and tricyclic heteroaromatic compounds. US2008146546; 2008
   Google Scholar
• Neurogen Corp. Substituted fused pyrroleoximes and fused pyrazoleoxyme. US2008032975; 2008
   Google Scholar
• Xu Yuelian. Substituted imidazopyrazine and triazolopyrazine derivatives: GABAA receptor ligands. US2006247245; 2006
   Google Scholar
• Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline urea derivatives. WO2008154442; 2008
   Google Scholar
• Helicon Therapeutics, Inc. Therapeutic pyrazoloquinoline derivatives. WO2008154438; 2008
   Google Scholar
• Helicon Therapeutics, Inc. Therapeutic pyrazolonaphthyridine derivatives. WO2008154447; 2008
   Google Scholar
• Helicon Therapeutics, Inc. Therapeutic 5,6,5-tricyclic analogs. WO2012051213; 2012
   Google Scholar
• Forskarpatent I SYD AB. New classes of GABAA/BZR ligands. WO2009123536; 2009
   Google Scholar
• Concert Pharmaceutical, Inc. Deuterium-modified triazolo-pyridazine derivatives as GABAA receptor modulators. WO2011005520; 2011
   Google Scholar
• Concert Pharmaceutical, Inc. Substituted benzimidazoles. WO2011047315; 2011
   Google Scholar
• Concert Pharmaceutical, Inc. Substituted triazolo-phthalazine derivatives. WO2011020044; 2011
   Google Scholar
• Concert Pharmaceutical, Inc. Substituted triazolo-pyridazine derivatives. WO2010025407; 2010
   Google Scholar
• Concert Pharmaceutical, Inc. 2-Aminonaphthiridine derivatives. WO2012116288; 2012
   Google Scholar
• Ge Healthcare Ltd. Carbolines and their use as imaging agents. WO2008132454; 2008
   Google Scholar
• GE Healthcare Ltd. Imaging agents. WO2009040377; 2009
   Google Scholar
• Universitat Wien. Novel piperine derivatives as GABAA receptors modulators. WO20110800313; 2011
   Google Scholar
• Cooke AJ, Hamilton MN. alpha-Subunit selective modulators of GABAA receptor function as CNS therapeutics. Expert Opin Ther Patent 2002;12:1491-501
   Web of Science ®Google Scholar
• Romanelli MN, Gualtieri F. The quest for the treatment of cognitive impairment:alpha7 nicotinic and alpha5 GABAA receptor modulators. Expert Opin Ther Patent 2007;17:1365-77
   Web of Science ®Google Scholar
• Zhang W, Koehler KF, Zhang P, Cook JM. Development of a comprehensive pharmacophore model for benzodiazepine receptor. Drug Des Discov 1995;12:193-248
   PubMedGoogle Scholar
• Brejc K, van Dijk W, Klassen R, et al. Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 2001;411:269-76
   PubMed Web of Science ®Google Scholar
• Ernst M, Bruckner S, Boresch S, Sieghart W. Comparative Models of GABAA Receptor Extracellular and Transmembrane Domains: important Insights in Pharmacology and Function 10.1124/mol.105.015982. Mol Pharmacol 2005;68:1291-300
   PubMed Web of Science ®Google Scholar
• Hanson SM, Czajkowski C. Structural mechanisms underlying benzodiazepine modulation of the GABAA receptor. J Neurosci 2008;28:3490-9
   PubMed Web of Science ®Google Scholar